About General Prognostics
General Prognostics is a Healthcare company based in Boston (United States) founded in 2020 by Javier Echenique, Sean Matsuoka, and Sidhant Jena. AI-based health monitoring tools are provided for healthcare professionals. It operates in the Healthcare and Technology sectors. General Prognostics has raised $3.25 million across 5 funding rounds from investors including UMass Lowell, NEC X and D4V. Its chief executive, as recorded, is Javier Echenique. Its focus areas include HealthTech, Healthcare IT, Value Based Care and Remote Monitoring. Its competitors include iRhythm Tech, AliveCor and Biotricity; 2 of its 3 listed competitors have raised funding.
Company details
General Prognostics was founded in 2020 in Boston, United States, and operates in the healthcare sector. AI-driven tools for health monitoring are developed, focusing on biomarker-based remote solutions for cardio-renal diseases. Blood analysis and remote monitoring capabilities are included, along with presymptomatic detection of critical conditions in patients. Services target healthcare professionals for improved patient outcomes.
- Total Equity Funding$3.25M (USD)
in 5 rounds
- InvestorsUMass Lowell
& 4 more
Funding Insights of General Prognostics
General Prognostics has successfully raised a total of $3.25M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.25M
- Total Rounds 5
- First Round $610,000
(Oct 2020)
- Investors Count 5
All 5 funding rounds of General Prognostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2024 | Seed | – | – | ||
| Jun 2024 | $200,000 | Debt – Conventional | – | – | – |
| Sep 2022 | $3.25M | Seed | – | D4V | |
| Apr 2021 | $25,000 | Grant | – | – | |
| Oct 2020 | $610,000 | Debt – Conventional | – | – | – |
5 investors in total: 3 institutional and 2 angel.
Investors in General Prognostics
General Prognostics has secured backing from 5 investors, including venture fund, angel, and institutional investors. Prominent investors backing the company include UMass Lowell, NEC X and D4V.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
NEC X is engaged in supporting early-stage tech startups. | 2018 | nec-x.com | Palo Alto, USA | |
Venture capital firm focusing on Japanese startups | d4v.com | Minato City, Japan | ||
Undergraduate and graduate education programs are provided across disciplines. | 1894 | uml.edu | United States | |
PM Pete Moran | unknown_1e40163b6a64403cb | |||
HK Hiroaki Kitano | unknown_0009f1657b3f4a789 |
Investor details for General Prognostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of General Prognostics
3 people are tracked at General Prognostics (3 in leadership).
| Name | Role | Group |
|---|---|---|
Javier Echenique | Co-Founder & CEO | Leadership |
Sean Matsuoka | Co-Founder | Leadership |
Sidhant Jena | Co-Founder | Leadership |
Complete people profiles for General Prognostics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of General Prognostics
3 dated milestones of General Prognostics across 4 years, from founding to its latest funding, stage changes and deals.
- Founded General Prognostics is founded.
- Funding First funding round of $610K.
- Funding Latest funding round, Seed,.
Competitors of General Prognostics
General Prognostics has 3 listed competitors in our database, 2 of them funded. They include iRhythm Tech, AliveCor and Biotricity.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| irhythmtech.com | 2006 | San Francisco, United States | $109.23M | 1,657 | Cloud-based ambulatory ECG monitors for cardiac arrhythmia diagnosis are provided. | |
| alivecor.com | 2010 | Mountain View, United States | $114.38M | 67 | Cardiac monitoring devices and applications are provided for heart health. | |
| biotricity.com | 2014 | San Francisco, United States | 55 | Developer of medical remote monitoring solutions that help prevent and manage chronic diseases |
Detailed competitors of General Prognostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of General Prognostics
The website of General Prognostics (gpx.ai) receives about 4.5K visits a month.
- Monthly visits4.5K
▼ 21.7% vs previous month
Top companies in Clinical IT & Data Platforms
3 companies that operate in the same segment as General Prognostics (Clinical IT & Data Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Employee health benefits are facilitated via a cloud-based platform. | 2007 | Plymouth Meeting, Pennsylvania, United States | USD 228.3 M | |||
Healthcare appointments are booked online via Zocdoc's platform. | 2007 | New York, New York, United States | USD 425.97 M | USD 4.66 M | 1,365 | |
Virtual physical therapy and digital pain care solutions are provided. | 2015 | San Francisco, California, United States | USD 854.44 M | 1,746 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about General Prognostics
Complete news archive for General Prognostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about General Prognostics
General Prognostics was founded in 2020.
General Prognostics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Javier Echenique is the CEO of General Prognostics, as recorded in our data. They have also founded this company.
General Prognostics is a funded company, having raised a total of $3.25M across 5 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $610K, raised on Oct 2020.
General Prognostics was founded in 2020 in Boston, United States, and operates in the healthcare sector. AI-driven tools for health monitoring are developed, focusing on biomarker-based remote solutions for cardio-renal diseases. Blood analysis and remote monitoring capabilities are included, along with presymptomatic detection of critical conditions in patients. Services target healthcare professionals for improved patient outcomes.
General Prognostics's top competitors include AliveCor, iRhythm Tech and Biotricity.
General Prognostics has 5 investors. Key investors include UMass Lowell, NEC X, D4V, Pete Moran, and Hiroaki Kitano.